Search 

River Cities Capital Fund is a private equity firm founded in 1994 and based in Cincinnati, Ohio. The firm manages approximately $500 million under management and is currently investing out of its 2014 vintage $200 fund. The firm looks to make investments of $5-$15 million initially up to $20 million over the investments lifetime. The firm is willing to invest throughout the United States and is looking to make approximately 4-6 equity investments over the next 6 to 9 months.

Twin Cities Angels is an angel group that was founded in 2006 that is based in Minnesota. The group has raised two funds that are The Twin Cities Angels Fund I and II. The second fund is currently looking to invest in emerging companies. The group typically provides seed and venture capital ranging from $ 25.000 to $2 million to life science companies. The group plans to invest in 4 to 6 companies per year. Twin Cities Angels seeks to invest in companies based in the Twin Cities Area of Minneapolis/St. Paul, the state of Minnesota and within a reasonable distance, such as Western Wisconsin, Northern Iowa, and Eastern Dakotas.

Z-Cube invests strategically in technologies that benefit Zambon’s pharmaceuticals and API chemical businesses. 

Within the therapeutics sector, Z-Cube is interested in new technological platforms that enable Zambon’s therapeutic innovation (Z-Cube does not make developmental-stage investments in new chemical entities, and as Zambon only markets small molecule therapeutics, technologies related to biologics are not of interest). This includes drug delivery innovations, and other enabling technologies for therapeutics that do not have to undergo the full therapeutic approval process in order to reach the marketplace. 

Z-Cube is also interested in diagnostics, particularly point of care diagnostics, companion diagnostics and other diagnostics that are used alongside a therapeutic intervention, and diagnostics that can be used in preventative care or to lower overall healthcare costs. Zambon is also interested in diagnostic technologies used to monitor a chronic condition. 

Zambon’s therapeutic focus areas are respiratory diseases and pain (particularly chronic pain), and the firm is also interested in CNS disorders and women’s health (encompassing osteoporosis and rheumatoid arthritis in addition to ob/gyn). However in the diagnostics sector, Zambon is interested in all indications. 

Zambon is additionally interested in digital technologies that enhance communication in the healthcare space, particularly between doctor and patient or between general practitioners and specialists. This includes EMR and telehealth technologies, and devices that transmit information wirelessly. 

Zambon is also interested in innovations in high-tech chemistry, including purification of APIs, advanced crystallography, and novel custom synthesis.